CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Clinical trial NCT05251714 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05251714
Sponsor: Treadwell Therapeutics, Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Breast Cancer

Start date: 2022-05-27
Primary completion: 2026-08-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.